相关临床试验
492
293 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1941
进行中（未招募）
37
7.5%
已完成
55
11.2%
尚未招募
256
52.0%
招募中
135
27.4%
终止
2
0.4%
Unknown
4
0.8%
撤回
1
0.2%
暂无批准数据
- The median real-world vein-to-vein time for a leading CAR-T therapy is 27 days, and shorter intervals are associated with meaningfully better complete-response rates and survival. - Most cell and gene therapies require storage at −150°C or colder, far beyond conventional pharmaceutical cold chain capabilities, with fresh un-frozen cells degrading within 12–96 hours. - Hospital readiness remains the defining access barrier across APAC, with Tier-2 regional centres frequently unqualified to receive cryogenic therapies even when the cold chain reaches the airport. - Point-of-care manufacturing, exemplified by India's NexCAR19 priced near US$50,000, offers an alternative model with vein-to-vein times of 7–14 days and no intercontinental cold chain dependency.
- India's Genome India Mission has sequenced over 10,000 individuals, building one of the world's largest genomic databases to accelerate precision medicine and research into genetic disorders. - Indian researchers have successfully demonstrated gene therapy for haemophilia, marking a milestone in indigenous medical innovation alongside the country's first indigenously researched antibiotics for drug-resistant infections. - Union Minister Dr. Jitendra Singh emphasized that India's vast genetic diversity offers an unprecedented opportunity to develop tailored treatments for Indian patients while contributing globally relevant healthcare solutions. - Policy initiatives including the BioE3 Policy, Bio-RIDE Mission, and Anusandhan National Research Foundation are strengthening India's biotechnology ecosystem and fostering collaboration across government, academia, and industry.
- A phase III trial from Tata Memorial Centre found that adding carboplatin to neoadjuvant chemotherapy significantly improved overall survival in triple-negative breast cancer patients, with a 5-year rate of 74.4% versus 66.8% in controls. - The survival benefit was exclusively observed in premenopausal patients, who showed both improved event-free survival (75.0% vs 59.6%) and overall survival (78.2% vs 64.6%) at 5 years. - Postmenopausal patients showed no benefit from carboplatin addition, suggesting biological differences between age groups that may guide personalized treatment approaches. - The study enrolled 717 patients over nearly a decade and represents a significant contribution to evidence-based care for triple-negative breast cancer in resource-limited settings.
- Tata Memorial Centre has signed a Memorandum of Understanding with GE HealthCare Technologies Inc. to establish a Cancer Research & Innovation Centre, with TMC serving as the clinical oncology partner and GE HealthCare as the technology partner. - The five-year collaboration will focus on accelerating development and validation of AI-based applications for medical imaging, clinical workflows, and advanced visualization tools in oncology care. - The partnership addresses the urgent need for enhanced cancer care as India faces a forecasted 12.8% rise in cancer incidence by 2025, with emphasis on early detection and equitable access challenges. - A Joint Working Group will chart key project areas including data annotation for application development and enterprise health informatics solutions to support personalized cancer care.
- The BART trial investigated adjuvant radiotherapy (ART) following radical cystectomy and chemotherapy in high-risk muscle-invasive bladder cancer (MIBC). - Results indicated that ART did not significantly increase severe acute or late toxicity compared to observation alone. - Grade 2 acute toxicities, mainly bowel-related, were more frequent in the ART arm but resolved without intervention. - The study suggests ART is a safe and tolerable option for MIBC, with ongoing assessment for oncological efficacy.
- President Droupadi Murmu launched India's first indigenously-developed CAR-T cell therapy, NexCAR19, marking a major breakthrough in the country's battle against cancer. - The therapy, developed through collaboration between IIT Bombay and Tata Memorial Centre with industry partner ImmunoACT, costs approximately one-tenth the price of international alternatives. - NexCAR19 represents the world's most affordable CAR-T cell therapy, making this advanced cancer treatment accessible to patients who previously couldn't afford the ₹4 crore international cost. - The launch positions India among the few countries capable of producing indigenous cellular therapy and demonstrates successful academia-industry partnership in biotechnology innovation.
